Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma

Wang, Chia-Chun; Cheng, Jason Chia‐Hsien; Tsai, Chiao-Ling; Lee, Jang-Ming; Huang, Pei-Ming; Lin, Chia Chi; Hsu, Chih-Hung; Hsieh, Min‐Shu; Chang, Yih‐Leong; Hsu, Feng-Ming

doi:10.1016/j.radonc.2015.03.019

Cited by 11 publications

(8 citation statements)

References 30 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,14 However, these single-institution studies were too small to resolve distinctiveness between groups. There was no attempt to access homogeneity within groups.…”

Section: Discussionmentioning

confidence: 99%

“…Although developed using patients undergoing esophagectomy with no preoperative therapy (pTNM), 12 use of 7th edition stage groups by two institutions demonstrated monotonically decreasing survival with increasing stage group for patients receiving neoadjuvant therapy (ypTNM). 13,14 However, these singleinstitution studies were too small to resolve distinctiveness between groups. There was no attempt to assess homogeneity within groups.…”

Section: The Literaturementioning

confidence: 99%

See 1 more Smart Citation

Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals

et al. 2016

View full text Add to dashboard Cite

We report analytic and consensus processes that produced recommendations for neoadjuvant pathologic stage groups (ypTNM) of esophageal and esophagogastric junction cancer for AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration (WECC) provided data for 22,654 patients with epithelial esophageal cancers; 7,773 had pathologic assessment after neoadjuvant therapy. Risk-adjusted survival for each patient was developed. Random Forest analysis identified data-driven neoadjuvant pathologic stage groups wherein survival decreased monotonically with increasing group, was distinctive between groups, and homogeneous within groups. An additional analysis produced data-driven anatomic neoadjuvant pathologic stage groups based only on ypT, ypN, and ypM categories. The AJCC Upper GI Task Force, by smoothing, simplifying, expanding, and assessing clinical applicability, produced consensus neoadjuvant pathologic stage groups. Grade and location were much less discriminating for stage grouping ypTNM than pTNM. Data-driven stage grouping without grade and location produced nearly identical groups for squamous cell carcinoma and adenocarcinoma. However, ypTNM groups and their associated survival differed from pTNM. The need for consensus process was minimal. The consensus groups, identical for both cell types were as follows: ypStage I comprised ypT0-2N0M0; ypStage II ypT3N0M0; ypStage IIIA ypT0-2N1M0; ypStage IIIB ypT3N1M0, ypT0-3N2, and ypT4aN0M0; ypStage IVA ypT4aN1-2, ypT4bN0-2, and ypTanyN3M0; and ypStage IVB ypTanyNanyM1. Absence of equivalent pathologic (pTNM) categories for the peculiar neoadjuvant pathologic categories ypTisN0-3M0 and ypT0N0-3M0, dissimilar stage group compositions, and markedly different early- and intermediate-stage survival necessitated a unified, unique set of stage grouping for patients of either cell type who receive neoadjuvant therapy.

show abstract

“…13,14 However, these single-institution studies were too small to resolve distinctiveness between groups. There was no attempt to access homogeneity within groups.…”

Section: Discussionmentioning

confidence: 99%

Section: The Literaturementioning

confidence: 99%

Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The achievement of pCR is associated with favorable prognosis in patients with EC undergoing neoadjuvant CRT, which have been documented by several studies [6,21]. Scheer et al undertook a comprehensive review of 22 articles to quantify the survival benefit of pCR [6].…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case–control study

Liu

Yang

Zhang

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

“…The present study also confirmed that negative resection margin was a significantly favorable prognostic factor for both PFS and OS in multivariate analysis ( p < 0.001). pCR rate following NACRT is known as 25%~30% [3, 15, 16] though its prognostic significance is still controversial [18, 19]. In the current study, pCR was achieved in 26.2% and it was not a significant factor on OS at 2 year (79.8% vs .…”

Section: Discussionmentioning

confidence: 50%

Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery

Cho

Ahn

et al. 2016

Oncotarget

View full text Add to dashboard Cite

This study is to evaluate the prognostic significance of supraclavicular and/or celiac lymph node (LN) metastases in locally advanced thoracic esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant chemoradiotherapy (NACRT) and surgery. Among the total 199 patients, 75 (37.7%) had supraclavicular and/or celiac LN metastasis. Surgery was performed following NACRT in 168 patients (84.4%). After the median 18.7 (1.0-147.2) months’ follow-up, 2-year rates of progression-free survival (PFS) and overall survival (OS) in all patients were 48.1% and 65.7%, respectively. In multivariate analyses, negative surgical margin (p < 0.001), ypT0 stage (p = 0.004), and ypN0 stage (p = 0.020) were significantly favorable factors for PFS, and negative surgical margin (p < 0.001) was the only significantly favorable factor for OS. Metastasis to the supraclavicular and/or celiac LNs was significant factor neither for PFS (p = 0.311) nor OS (p = 0.515). Supraclavicular and/or celiac LN metastasis did not compromise the clinical outcomes following NACRT and surgery.

show abstract

Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma

Cited by 11 publications

References 30 publications

Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals

Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals

Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case–control study

Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery

Contact Info

Product

Resources

About